
Lumiliximab
CAS No. 357613-86-6
Lumiliximab( —— )
Catalog No. M36903 CAS No. 357613-86-6
Lumiliximab (IDEC-152) is a primate-ized chimeric antibody targeting CD23 rhesus monkey/human chimeric antibody with inhibitory effects on IgE antibody production for the study of allergic diseases.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 301 | Get Quote |
![]() ![]() |
5MG | 591 | Get Quote |
![]() ![]() |
10MG | 938 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameLumiliximab
-
NoteResearch use only, not for human use.
-
Brief DescriptionLumiliximab (IDEC-152) is a primate-ized chimeric antibody targeting CD23 rhesus monkey/human chimeric antibody with inhibitory effects on IgE antibody production for the study of allergic diseases.
-
DescriptionLumiliximab (Anti-CD23 Recombinant Antibody) is an anti-CD23 monoclonal antibody that inhibits allergen-induced responses.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number357613-86-6
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Poole JA, et al. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol. 2005 Oct;116(4):780-8.?
molnova catalog



related products
-
Pro-xylane
Pro-xylane (Hydroxypropyl tetrahydropyrantriol) is a biologically active C-glycoside in aqueous media, acts as an activator of glycosaminoglycans (GAGs) biosynthesis.
-
AI-10-47
AI-10-47 is a small molecule inhibitor of CBFβ-RUNX binding(IC50 : 3.2 μM).
-
SID-852843
SID-852843 is a WNV NS2B-NS3 protease inhibitor with an IC50 value of 0.105 μM for WNV NS2B-NS3 protease and can be used for the study of viral infections.